The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
The effects of exercise on metabolic control in type II diabetic patients given glimepiride or glibenclamide were studied in a multinational phase II clinical trial (14 centers in 4 countries). A total of 167 type II diabetic out-patients (117 men, 50 women) completed the trial as planned. The study was of parallel group, 2 x 2 factorial design: patients were first stabilized in a randomized, double-blind manner on 3 mg of glimepiride or 10 mg of glibenclamide treatment once daily over 14-28 days and were then assigned in randomized open fashion to a group with or without exercise. Exercise consisted of riding a bicycle ergometer for 1 hour at pulse rate 120 beats per minute. Three-hour blood glucose, insulin, and C-peptide profiles were made after the stabilization phase (baseline profiles) and 7 days later with or without exercise (endpoint profiles). Pairwise comparisons of changes in blood glucose AUC/1-3 h revealed a statistically significant decrease in patients who exercised vs those who did not, which was comparable for both sulfonylureas used. There was a statistically significant decrease in C-peptide AUC/1-3 h and insulin AUC/1-3 h in the glimepiride exercise group vs the glimepiride group without exercise. Physical exercise did not lead to statistically significant changes in C-peptide AUC/1-3 h and insulin AUC/1-3 h under glibenclamide treatment. In conclusion, a blood-glucose-lowering response to acute exercise was demonstrated in type II diabetic patients treated with either sulfonylurea, but a significant suppression of endogenous insulin secretion was observed for glimepiride only.